Specialty drugs account for fewer than 3% of all prescriptions written in the United States. Yet they represent more than 50% of total drug spending and that share is growing every year. For health plans, PBMs, TPAs, and employers, the financial pressure is real and intensifying. Members who struggle to cover the costs of care are trusting their providers and health plans to recommend the most effective care.
Utilization management (including prior authorization) sits squarely at the center of this tension. When done well, UM ensures patients receive clinically appropriate, evidence-based care while protecting payers and patients from avoidable and unsustainable cost exposure. When done poorly, in opaque and inconsistent ways, it becomes a barrier to care that harms patients, frustrates physicians, and exposes organizations to regulatory and reputational risk.
The stakes are high and rising. Understanding how rigorous, independent UM actually works for specialty drugs is strategically and clinically imperative.
What Makes Specialty Drugs Different
High-cost specialty drugs are biologically complex therapies, including biologics, gene therapies, immunologics, and targeted oncology agents designed to treat serious, often rare or complex conditions. Costs can range from $5,000 per year for some biologics to well over $1 million for a single gene therapy treatment.
That price range reflects genuine clinical complexity. These therapies often target small patient populations, require specialized administration, and demand ongoing monitoring to assess response and safety. The clinical criteria governing their use are sophisticated, evolving rapidly, and highly specific to each subspecialty.
This is precisely why standard UM approaches fall short. A generalist reviewer applying broad clinical criteria to a gene therapy for a rare metabolic disorder is not equipped to make a sound determination. The science moves too fast, the populations too narrow, and the clinical nuance too deep for one-size-fits-all review. This complexity carries directly into how utilization management must be structured.
The Utilization Management Framework
Effective specialty drug UM operates across three stages, each serving a distinct clinical purpose.
Prior authorization establishes clinical necessity before treatment begins. For high-cost specialty drugs, this is a meaningful clinical checkpoint that protects patients from therapies that may not match their clinical profile and protects payers from expenditures with no corresponding benefit.
Concurrent review monitors ongoing treatment appropriateness. For specialty therapies, treatment trajectories can shift. A therapy that was clinically appropriate at initiation may need reassessment as patient response, disease progression, or emerging evidence changes the picture.
Retrospective review evaluates outcomes and cost-effectiveness following treatment. For value-based contracting and outcomes-linked agreements (a growing trend in specialty drug management), retrospective data is foundational.
Step therapy and evidence-based clinical criteria round out the framework, ensuring that treatment pathways reflect current clinical evidence rather than financial defaults.
________________________________________
What Good Utilization Management Actually Looks Like
Evidence-based, specialty-matched clinical criteria are the foundation for good utilization management. Every review should be grounded in current clinical evidence, not outdated criteria, financial targets, or administrative convenience. For specialty drugs, that means criteria developed and applied by reviewers with genuine subspecialty expertise in the condition and therapy being reviewed.
Specialty-matched physician reviewers are critical to a quality case review. When a health plan or PBM routes an oncology review to a generalist, or a rare disease case to a reviewer unfamiliar with the therapeutic landscape, the result is neither clinically sound nor defensible on appeal. Physician reviewers must be matched to the specialty of the case.
Turnaround times matter for both compliance and for patient outcomes. Meeting or exceeding CMS standards (72 hours for urgent reviews, seven days for standard) is not just a regulatory requirement. It is a clinical one. Delays in specialty drug authorization have direct consequences for patients managing serious conditions.
Transparent and written denial documentation is essential. Meaningful appeals require meaningful explanations. When payers cannot provide clear, evidence-based rationale for an adverse determination, they undermine the entire process and expose themselves to regulatory and legal risk.
Monitoring for disparate outcomes across patient populations should be a standard operational practice. Organizations serious about health equity cannot rely on external enforcement to identify disparities. They need internal visibility and analytical infrastructure to act on what they find.
The Case for Independent Review
Each of these best practices points toward the same conclusion: independent, physician-led review is the most defensible approach to specialty drug UM because it removes the financial conflicts that make in-house payer review vulnerable to criticism.
When a reviewer has no stake in the outcome of a coverage determination, the decision rests entirely on clinical evidence. That objectivity is not just ethically important. It is operationally valuable. Independent review produces decisions that hold up under appeal, withstand regulatory scrutiny, and can be documented and defended with transparency.
Organizations like MRIoA bring a combination of clinical depth, subspecialty breadth, and independence that in-house UM programs structurally cannot replicate. With more than 700 state-matched specialists spanning 150+ specialties, and a data infrastructure built on over 10 million clinical reviews, MRIoA provides the clinical rigor and analytical foundation that specialty drug UM demands.
Looking Ahead
The specialty drug pipeline shows no signs of slowing. Gene and cell therapies, value-based contracting models, AI-assisted UM tools, and continued CMS regulatory evolution will all reshape how payers manage high-cost therapies over the next several years. Each of these trends raises new questions about clinical criteria, outcomes measurement, and equitable access.
What will not change is the standard by which utilization management will be judged: does it ensure the right patient receives the right treatment at the right time or does it introduce barriers that serve financial interests at the expense of clinical ones?
Done right, UM is not the enemy of access to high-cost specialty drugs. It is one of its most important safeguards. The goal is getting it right every time, for every patient.
To learn more about how MRIoA supports health plans, PBMs, and TPAs in building clinically rigorous, defensible utilization management programs for specialty drugs, schedule a consultation with our team.
